Finally, in terms of knowledge translation this intervention is best suited for a universal or managed care setting. Acknowledgements SB Jaglal is the Toronto Rehabilitation Institute Chair at the University of Toronto; G Hawker is The Arthritis Society Senior Distinguished Rheumatology Investigator and FM Hill Chair in Academic Women’s Medicine, Women’s College Hospital; SM Cadarette holds a Canadian Institutes of Health Research New Investigator Award; SR Majumdar is an Alberta Heritage Foundation for Medical Research Health scholar. A Papaioannou holds the Eli Lilly Canada Chair in Osteoporosis. Dr. Marita Kloseck is the recipient of an unrestricted
research grant from Procter & Gamble. This
study was funded by a grant from the Ontario Ministry of Health and Long-Term Care Osteoporosis Strategy. Research learn more at Toronto Rehabilitation Institute is supported in part by funding under the Provincial Rehabilitation Research Program Cytoskeletal Signaling inhibitor from the Ministry of Health and Long-Term Care in Ontario. The views expressed do not necessarily reflect those of the Ministry. Equipment and space have been funded with grants from the Canada Foundation for Innovation, Ontario Innovation Trust, and the Ministry of Research and Innovation. Trial Registration Number: ClinicalTrials.gov Identifier: NCT00511693. Conflicts of interest None. Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. References 1. Brown JP, Josse RG, Scientific Advisory Council of the Osteoporosis Society of Carteolol HCl Canada (2002) Clinical practice guidelines
for the diagnosis and management of osteoporosis in Canada. CMAJ 167(10 Suppl):S1–S34PubMed 2. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown J, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD (2010) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2010. doi:10.1503/cmaj.100771 3. Center JR, Bliuc D, Nguyen TV, Eisman JA (2007) Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 297(4):387–394PubMedCrossRef 4. Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE (2004) Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 15(10):767–778PubMedCrossRef 5. Giangregorio L, Papaioannou A, Cranney A, Zytaruk N, Adachi JD (2006) Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum 35(5):293–305PubMedCrossRef 6. Heaney RP (2003) Advances in therapy for osteoporosis. Clin Med Res 1(2):93–99PubMedCrossRef 7.